Add BrightSurf on Google Email

More than skin-deep

A team of Kyoto University researchers found that macrophages produce granulomas through a hyperactive metabolic pathway called the pentose phosphate pathway. Inhibition of this pathway showed therapeutic efficacy in reducing granuloma formation in vitro and in mouse tissue models.

SourceKyoto University·JournalJournal of Clinical Investigation·TypeExperimental study·DateDec 6, 2023

Hard to drug: Protein droplets reveal new ways to inhibit transcription factors in an aggressive form of prostate cancer

Researchers have discovered a new approach to targeting transcription factors in prostate cancer by exploiting the formation of protein droplets. This process can be used to inhibit androgen receptor activity, which is essential for the growth and survival of cancer cells.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalNature Structural & Molecular Biology·DateDec 4, 2023

Applications of macrocyclic molecules in cancer therapy: Target cancer development or overcome drug resistance

Researchers have identified macrocyclic compounds as a potential solution for targeting proteins critical to tumorigenesis, blocking nearly 80% of cancer's signature characteristic events. Additionally, these small compact molecules can effectively overcome drug resistance by binding to mutant proteins and inhibiting their activities.

SourceSichuan International Medical Exchange and Promotion Association·JournalMedComm – Oncology·TypeLiterature review·DateNov 29, 2023

Three new articles in the Journal of Pharmaceutical Analysis demonstrate the potential of natural compounds to treat gastrointestinal disorders

Researchers found that 1,8-cineole inhibits inflammatory pathways in the gut, while ginsenoside Rk2 alleviates liver inflammation and restores intestinal barrier function. Another compound, specnuezhenide, modifies gut microbiota and has potential to inhibit colorectal tumor growth.

SourceCactus Communications·JournalJournal of Pharmaceutical Analysis·TypeExperimental study·DateNov 27, 2023

Bone growth drug may reduce sudden infant death syndrome in children with common form of dwarfism

A new study found that vosoritide treatment increases height, facial volume, and foramen magnum size in young children with achondroplasia, reducing sudden infant death syndrome, sleep apnea, and surgery needs. Vosoritide may improve quality of life and potentially save lives by addressing the root cause of the condition.

SourceMurdoch Childrens Research Institute·JournalThe Lancet Child & Adolescent Health·TypeRandomized controlled/clinical trial·DateNov 21, 2023

Cancer stem cells trigger macrophage aging

Researchers at Hokkaido University found that cancer stem cells cause macrophages to age, suppressing their antitumor activity. Supplementing mice with nicotinamide mononucleotide restored macrophage function and prevented tumor growth.

SourceHokkaido University·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateNov 14, 2023

Korea University and Ewha Womans University researchers highlight advancements in biomedical research with enzyme-activated fluorescent probes

Researchers have summarized recent advances in enzyme-activated near-infrared fluorescent probes for non-invasive visualization of enzyme dynamics and disease status. These probes offer high specificity, sensitivity, and biocompatibility, making them valuable assets in biomedical research and healthcare.

SourceKorea University College of Medicine·JournalTrAC Trends in Analytical Chemistry·TypeLiterature review·DateNov 14, 2023

C-Path’s pioneering neuroscience workshop transforms the landscape of neurological disorder therapies

The C-Path Neuroscience Annual Workshop brought together stakeholders to chart a transformative course for neurology research and drug development, focusing on chronic progressive diseases such as Alzheimer's and Parkinson's. Key highlights included recommendations for innovative therapies and tools to address complex disorders.

SourceCritical Path Institute (C-Path)·JournalNeurotherapeutics·TypeContent analysis·DateNov 9, 2023

Survey reveals 42% of primary care physicians are unfamiliar with biologics to treat asthma

A survey found that 42% of primary care physicians are unaware of biologic treatments for asthma, and 82% do not get necessary labs to determine treatment options. This lack of knowledge can lead to delayed referrals to asthma specialists and reduced effectiveness in managing symptoms.

SourceAmerican College of Allergy, Asthma, and Immunology·JournalAnnals of Allergy Asthma & Immunology·TypeSurvey·DateNov 9, 2023

Scientists engineer potent immune cells for ‘off-the-shelf’ cancer immunotherapy

Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.

RCSI study shows survival benefit of augmentation therapy for people with the genetic lung condition AATD

A new study by RCSI University of Medicine and Health Sciences found that boosting levels of a deficient protein improves survival rates for people with severe alpha-1 antitrypsin deficiency. The research, which tracked health data from over 600 patients, showed a clear survival benefit from augmentation therapy.

SourceRCSI·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateNov 1, 2023

First classification of four stages of heart attack based on heart muscle damage is released

A new classification system for heart attacks based on heart muscle damage is released, offering a more differentiated definition and improving understanding of acute atherothrombotic MI. This system has the potential to stratify risk more accurately and lay the groundwork for development of injury-stage-specific therapies.

SourceElsevier·JournalCanadian Journal of Cardiology·TypeMeta-analysis·DateOct 31, 2023

Anti-anxiety drug may improve brain cancer survival chances

A new study published in Science Advances suggests that a decades-old anti-anxiety drug can improve the effectiveness of chemo-radiotherapy towards glioblastoma, the most common and lethal brain cancer. The researchers found that the drug trifluoperazine can re-sensitize tumor cells to both therapies, leading to improved patient survival.

SourceFlinders University·JournalScience Advances·TypeExperimental study·DateOct 25, 2023

Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus

A secondary analysis of the SWOG S0931 trial found that patients with very-high risk clear-cell renal cell carcinoma who received adjuvant everolimus after surgery had a statistically significant improvement in recurrence-free survival. The results suggest that everolimus may be beneficial for this high-risk patient population, but als...

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateOct 21, 2023

First-of-its kind hormone replacement treatment shows promise in patient trials

A new hormone replacement therapy, Pulsatility, has shown promising results in improving symptoms and quality of life for patients with adrenal insufficiency conditions. The treatment, which delivers hydrocortisone in a pulsatile pattern, decreased fatigue by 10% and improved mood and energy levels by 30%.

SourceUniversity of Bristol·JournalJournal of Internal Medicine·TypeRandomized controlled/clinical trial·DateOct 19, 2023

Mitochondrial protein plays key role in glioblastoma and therapeutic resistance

Researchers found that mitochondrial protein CHCHD2 is associated with increased tumor growth, invasion, and resistance to chemotherapy in glioblastoma patients. CHCHD2 interacts with mutated EGFR to increase sensitivity to cytotoxic drugs, highlighting its potential as a therapeutic target.

SourceCarl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign·JournalInternational Journal of Oncology·TypeExperimental study·DateOct 17, 2023

Research in the Special Issue of Journal of Pharmaceutical Analysis uncovers previously unexplored cellular mechanisms

Researchers have discovered new insights into microglia-astrocyte communication and its impact on intracerebral hemorrhage, as well as the testicular toxicity of triptolide. Additionally, a study on epicardial cells has identified key gene markers associated with cardiac regenerative therapy strategies.

SourceCactus Communications·JournalJournal of Pharmaceutical Analysis·TypeExperimental study·DateOct 16, 2023

Capturing immunotherapy response in a blood drop

A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.

SourceJohns Hopkins Medicine·JournalNature Medicine·DateOct 9, 2023

New study at the Alzheimer’s Center at Temple casts light on protein that could help defeat Alzheimer’s disease and increase productive lifespan

Scientists at Temple University's Alzheimer's Center have identified a promising new therapeutic target for Alzheimer's disease: the protein ABCA7. The study found that cholesterol depletion and inflammation suppress ABCA7 levels in human brain cells, potentially contributing to disease onset.

Esketamine nasal spray: an option for patients with treatment-resistant depression

A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.

SourceChampalimaud Centre for the Unknown·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateOct 4, 2023

Semaglutide significantly improves blood sugar control and weight loss in adults with type 2 diabetes for up to 3 years in real-world study

A real-world study of over 23,000 adults with type 2 diabetes found that semaglutide significantly improved blood sugar control and weight loss for up to 3 years. The study showed that patients who had never taken a GLP-1 RA or those with higher adherence achieved more pronounced reductions in blood sugar levels and weight loss.